pp 1-10 | Cite as

Computational Design of Multi-target Kinase Inhibitors

  • Sinoy Sugunan
  • Rajanikant G. K.
Part of the Methods in Pharmacology and Toxicology book series


As key regulators of every aspect of cell function, protein kinases are frequently associated with various human diseases. Therefore, protein kinase inhibition has become the second most important group of drug targets, after G-protein-coupled receptors. Owing to the complex and polygenic nature of diseases, designing multi-kinase small molecule inhibitors as potential therapies is gaining major consideration. Effective in silico drug design strategies are desired to identify multi-target kinase inhibitors. In this chapter, we summarize the two such effective computational strategies reported by our group to identify multi-target kinase inhibitors.


Ensemble pharmacophore Molecular docking Molecular dynamics simulation Multi-target inhibitor Protein kinase Virtual screening 


  1. 1.
    Wu P, Nielsen TE, Clausen MH (2016) Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov Today 21:5–10Google Scholar
  2. 2.
    Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28–39Google Scholar
  3. 3.
    Wu P, Nielsen TE, Clausen MH (2015) FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36:422–439Google Scholar
  4. 4.
    Yaish P, Gazit A, Gilon C et al (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242:933–935Google Scholar
  5. 5.
    Divito SJ, Kupper TS (2014) Inhibiting Janus kinases to treat alopecia areata. Nat Med 20:989–990Google Scholar
  6. 6.
    Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14:219–232Google Scholar
  7. 7.
    Wu P, Hu Y (2012) Small molecules targeting phosphoinositide 3-kinases. MedChemComm 3:1337–1355Google Scholar
  8. 8.
    Wu P, Hu YZ (2010) PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr Med Chem 17:4326–4341Google Scholar
  9. 9.
    Li YH, Wang PP, Li XX et al (2016) The human kinome targeted by FDA approved multi-target drugs and combination products: a comparative study from the drug-target interaction network perspective. PLoS One 11:e0165737Google Scholar
  10. 10.
    Rask-Andersen M, Zhang J, Fabbro D et al (2014) Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci 35:604–620Google Scholar
  11. 11.
    Yang H, Qin C, Li YH et al (2016) Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res 44:D1069–D1074Google Scholar
  12. 12.
    Boran ADW, Iyengar R (2010) Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel 13:297–309Google Scholar
  13. 13.
    Dar AC, Das TK, Shokat KM et al (2012) Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486:80–84Google Scholar
  14. 14.
    Korcsmáros T, Szalay MS, Böde C et al (2007) How to design multi-target drugs: target search options in cellular networks. Expert Opin Drug Discov 2:799–808Google Scholar
  15. 15.
    Zhang S (2011) Computer-aided drug discovery and development. In: Satyanarayanajois SD (ed) Drug design and discovery: methods and protocols. Humana Press, Totowa, NJ, pp 23–38Google Scholar
  16. 16.
    Ma XH, Shi Z, Tan C et al (2010) In-silico approaches to multi-target drug discovery. Pharm Res 27:739–749Google Scholar
  17. 17.
    Clemente JC, Govindasamy L, Madabushi A et al (2006) Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Acta Crystallogr Sect D 62:246–252Google Scholar
  18. 18.
    Wei D, Jiang X, Zhou L et al (2008) Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem 51:7882–7888Google Scholar
  19. 19.
    Nair SB, Fayaz SM, Rajanikant GK (2013) A novel multi-target drug screening strategy directed against key proteins of DAPk family. Comb Chem High Throughput Screen 16:449–457Google Scholar
  20. 20.
    Fayaz SM, Rajanikant GK (2015) Ensembling and filtering: an effective and rapid in silico multitarget drug-design strategy to identify RIPK1 and RIPK3 inhibitors. J Mol Model 21:314Google Scholar
  21. 21.
    Zou J, Xie HZ, Yang SY et al (2008) Towards more accurate pharmacophore modeling: multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2. J Mol Graph Model 27:430–438Google Scholar
  22. 22.
    Ren J, Xie L, Li WW et al (2010) SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison. Nucleic Acids Res 38:441–444Google Scholar
  23. 23.
    Fayaz SM, Rajanikant GK (2014) Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors. J Comput Aided Mol Des 28:779–794Google Scholar
  24. 24.
    Cui Z, Chen S, Wang Y et al (2017) Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment. Eur J Med Chem 136:372–381Google Scholar
  25. 25.
    Cui Z, Li X, Li L et al (2016) Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment. Bioorg Med Chem 24:261–269Google Scholar
  26. 26.
    Reker D, Seet M, Pillong M et al (2014) Deorphaning pyrrolopyrazines as potent multi-target antimalarial agents. Angew Chem Int Ed 53:7079–7084Google Scholar
  27. 27.
    Rehan M (2015) A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches. J Mol Graph Model 62:226–234Google Scholar
  28. 28.
    Ajmani S, Viswanadhan VN (2013) A neural network-based QSAR approach for exploration of diverse multi-tyrosine kinase inhibitors and its comparison with a fragment-based approach. Curr Comput Aided Drug Des 9:482–490Google Scholar
  29. 29.
    Marzaro G, Chilin A, Guiotto A et al (2011) Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. Eur J Med Chem 46:2185–2192Google Scholar
  30. 30.
    Wassermann AM, Peltason L, Bajorath J (2010) Computational analysis of multi-target structure-activity relationships to derive preference orders for chemical modifications toward target selectivity. ChemMedChem 5:847–858Google Scholar
  31. 31.
    Allen BK, Mehta S, Ember SWJ et al (2015) Large-scale computational screening identifies first in class multitarget inhibitor of EGFR kinase and BRD4. Sci Rep 5:16924Google Scholar
  32. 32.
    Hsu K-C, Cheng W-C, Chen Y-F et al (2012) Core site-moiety maps reveal inhibitors and binding mechanisms of orthologous proteins by screening compound libraries. PLoS One 7:e32142Google Scholar

Copyright information

© Springer Science+Business Media New York 2018

Authors and Affiliations

  1. 1.School of BiotechnologyNational Institute of Technology CalicutCalicutIndia

Personalised recommendations